Hydrocodone/chlorphenamine extended-release - Covidien

Drug Profile

Hydrocodone/chlorphenamine extended-release - Covidien

Alternative Names: Chlorphenamine/hydrocodone; Chlorpheniramine/hydrocodone; Hydrocodone/chlorpheniramine; TussiCaps

Latest Information Update: 17 Nov 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mallinckrodt Inc.
  • Developer Covidien
  • Class Antiallergics; Antitussives; Indazoles; Indoles; Morphinans; Opioid analgesics; Sedating antihistamines
  • Mechanism of Action Histamine H1 receptor antagonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cough

Most Recent Events

  • 17 Apr 2014 Hi-Tech Pharmacal has been acquired by Akorn
  • 26 Aug 2011 Hydrocodone/chlorphenamine extended-release licensed to Hi-Tech Pharmacal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top